2胃癌领域基础知识分析.ppt

* * OS改善，PFS未见明显差异，总有效率提高 * * The Median OS was 285 days (95% CI: 265-305 days) [9.4 months] for patients treated with 5-FU and 322 days (95% CI 300-343 days) [10.6 months] for patients treated with Capecitabine, giving an unadjusted hazard ratio (HR) of 0.87 (95% CI: 0.77-0.98) in favour of Capecitabine (p=0.027). Okines et al. ESMO 2008 * There was no significant difference in PFS between the two treatment groups (unadjusted HR 0.91. 95% CI 0.81-1.02, p=0.0925), with a median PFS of 182 days in the 5-FU group (95% CI 167-197days) [6.0 months] and 199 days in the Capecitabine group (95% CI 1